Navigation Links
New drug now available for actinic keratosis
Date:3/14/2012

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine. The gel, called ingenol mebutate, is applied to the skin for just a few days, making it quicker and even more effective as current therapies require weeks to months to apply. The Phase III study results of the trial are published in the March 15, 2012 issue of the The New England Journal of Medicine.

Actinic keratoses are premalignant skin lesions very common in fair-skinned individuals who always burn and rarely tan. It is the most common precursor to sun-related squamous-cell carcinoma, the second most common type of skin cancer. Current topical medications to treat actinic keratosis often causes skin irritation and result in many patients not completing the full treatment regimen. Topical gels are used as an alternative treatment to cryosurgery, a method of freezing lesions using liquid nitrogen as the cooling solution, to destroy the precancerous skin lesions. Cryosurgery is the most common form of treatment, but is only practical in treating areas with single lesions, not multiple lesions.

"The shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis," said Mark Lebwohl, MD, lead study author and Professor and Chair of the Department of Dermatology at Mount Sinai School of Medicine. "Many patients find it difficult to stick with the current regimen. The shorter period is a more effective option for patients who don't want a treatment that interferes with their everyday lives for weeks or even months."

Ingenol mebutate is derived from the active ingredient in the sap of the plant Euphorbia peplus, which has long been used as a traditional remedy for common skin lesions. The study found patients require just two to three days of application with results comparable or improved to rates of current actinic keratosis clearance. The shorter treatment period also results in 98 percent of patients completing the full treatment regimen.

Researchers studied two cohorts; 547 patients with actinic keratoses on the face or scalp and 458 patients with actinic keratoses on the trunk or extremities. About half of each group received ingenol mebutate with the other half receiving a placebo. The first group applied treatment at a .015 percent concentration for three days and the second at a .05 percent concentration for two days. At the end of the evaluation period, 42 percent of the first group that received ingenol mebutate and 34 percent of the second group showed complete clearance of actinic keratosis, compared to about 4 and 5 percent, respectively, of the placebo groups.

The approval of ingenol mebutate was announced at the 2012 The American Academy of Dermatology's Annual Meeting and is currently available for prescription under the name Picato.


'/>"/>
Contact: Jeanne Bernard
Jeanne.Bernard@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. First-in-human drug for malignant glioma available in experimental trial
2. Discordance among commercially-available diagnostics for latent TB infection
3. Combination of available tests helps predict Alzheimers disease risk
4. Incisionless surgery now available as an investigational treatment for esophageal disorder
5. Grays Anatomy for Students, worlds bestselling anatomy textbooks, now available on iPad
6. Drug recognition program available for Texas employers
7. Brain Scans to Spot Alzheimers May Be Available This Year
8. Summary of NCRP Workshop on CT in Emergency Medicine, now available
9. Updated agenda available for Optimizing PCI Outcomes Symposium
10. Wiley-Blackwell announces 102 additional products available through Research4Life
11. Brochures explaining new health care law to patients available free in English and Spanish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... of a growing number of cancers and is touted to be the next revolution ... treatment, thus far, has been in the form of immune checkpoint inhibitors such as ...
(Date:3/29/2017)... ... , ... AvePoint , the Microsoft Cloud expert, is pleased to announce ... at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ... and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017   Dynatronics Corporation (NASDAQ: ... Cynthia L. McHenry (Cyndi) as Vice ... leading Dynatronics manufacturing, distribution, and purchasing operations across ... CEO Kelvyn H. Cullimore, Jr. ... process conducted by the company as it continues ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number of advantages ... economic arguments also favor its legalization. The benefits include increased ... to legalize and regulate marijuana requires an ecosystem of support ... SING Profile ), American Cannabis Company (OTC: AMMJ), Kush Bottles, ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: